Bristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program And Commitment To Exploring Novel Combinations At ASCO 2017

BMS compounds to be featured in more than 80 presentations spanning 20 types of cancer, with focus on research of precision therapies aimed at improving standards of care

First efficacy data for investigational anti-LAG-3 in combination with Opdivo in anti-PD-1/PD-L1 relapsed or refractory patients and for Opdivo in combination with epacadostat showcases next wave of cancer research approaches

Opdivo plus Yervoy data to be featured in 18 presentations across multiple tumor types, including advanced small cell lung cancer, melanoma and colorectal cancer

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that more than 80 presentations, including 16 oral presentations and seven poster discussions, highlighting data from Company-sponsored studies, collaborations and investigator-sponsored research evaluating its oncology compounds across 20 types of cancer, will be featured at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 in Chicago from June 2-6. Results to be presented represent the breadth of the Company’s Oncology research portfolio, including monotherapy and combination studies of Opdivo (nivolumab) and Yervoy (ipilimumab), as well as studies of Empliciti (elotuzumab) and Sprycel (dasatinib). The Company will also present updates from its robust investigational pipeline, including proof-of-concept efficacy data for its anti-lymphocyte activation gene-3 (LAG-3) monoclonal antibody in combination with Opdivo and pharmacokinetic, pharmacodynamic and safety data on its investigational glucocorticoid-induced tumor necrosis factor receptor-related gene (GITR) agonist alone and for the first time, in combination with Opdivo in advanced solid tumors.

Several presentations will report data from clinical collaborations supportive of the Company’s efforts to advance understanding of the potential role for Opdivo in combination with novel mechanisms of action for several tumor types, including the first presentation of data evaluating the safety and efficacy of Opdivo in combination with epacadostat, Incyte’s selective IDO1 enzyme inhibitor. Presentations featuring translational medicine research underscore Bristol-Myers Squibb’s scientific leadership in driving understanding of how a patient’s tumor biology can potentially guide treatment decisions.